Highest-materiality recent filing
Utah Medical Products appoints director Carrie Leigh, raises dividend 1.7% to $0.305
Board increased to 6 members; appointed Carrie Leigh, daughter of CEO Kevin Cornwell, effective Nov 1, 2024.
UTMD FY2023 EPS up 1% on interest income; revenue down 4%, litigation costs rise
Full year revenue $50.2M (-4% YoY); EPS $4.574 (+1.2%) as lower operating income offset by higher interest income.
UTMD Q1 2023: NI +19.2% to $4.2M, EPS $1.16; OUS sales +23%; cash $80.9M
Consolidated sales $12.5M, up 1.6% YoY; OUS sales up 23% (28% constant currency), domestic down 10%.
UTMD Q4 EPS $1.253, up 11% YoY; FY22 EPS $4.522, up 12%; dividend raised to $0.295
Q4 revenue $13.6M (+5.1% YoY); FY22 revenue $52.3M (+6.6% YoY); constant currency sales up ~10% for the year.
UTMD Q1 2022 revenue +12.4%, EPS +16.6%; operating margin expands to 36.7%
Revenue $12.3M, up 12.4% YoY; domestic sales +18%, OUS +4% (constant currency +7%).
UTMD Q4 EPS $1.127; FY2021 sales $49.1M, net income up 37% YoY
Diluted EPS Q4 $1.127 (up 20.6% YoY); FY GAAP EPS $4.041, non-GAAP $4.147.
UTMD Q3 2021 EPS $1.150, revenue up 20%; 9M non-GAAP EPS $3.021, up 46%
Q3 2021 net income $4.2M (33.5% of sales), up 43.4% YoY; diluted EPS $1.150.
UTMD Q2 net income up 161%, EPS $0.937; revenue $12.6M (+43%); guides FY EBITDA ~$25M
Q2 revenue $12.6M (+43% YoY); domestic +46%, OUS +40%; constant-currency sales +40%.
On November 1, 2024, the Board of Directors of Utah Medical Products, Inc. (UTMD) voted to increase the size of the Board of Directors from five to six members and to appoint Carrie Leigh to fill the vacancy created by the increase in the number of directors.
Max materiality 0.80 · Median 0.40 · Most common event earnings